Breaking News
October 16, 2018 - Health Highlights: Oct. 12, 2018
October 16, 2018 - Study holds promise for new pediatric brain tumor treatment
October 16, 2018 - Patient advocate uses MRI scans to create art and spark conversations about life with illness
October 16, 2018 - Fish oil based diets may suppress growth and spread of breast cancer cells
October 16, 2018 - Number of VHA facilities offering acupuncture has increased rapidly
October 16, 2018 - Influential Leapfrog Group jumps in to rate 5,600 surgery centers
October 16, 2018 - HIV-infected infants more likely to acquire congenital cytomegalovirus infection
October 16, 2018 - Study pinpoints new marker that can predict Crohn’s disease subtype
October 16, 2018 - Simple procedure could be efficacious intervention for failed back surgery
October 16, 2018 - New research identifies modifiable dementia risk factor in elderly people
October 16, 2018 - Zebrafish study uncovers molecular ‘brake’ that helps control eye lens development
October 16, 2018 - Overlapping copy number variations underlie autism and schizophrenia in Japanese patients
October 16, 2018 - Majority of Americans’ ancestry can be traced through existing DNA databases
October 16, 2018 - Patients coerced into mental health care less likely to perceive treatment as effective
October 16, 2018 - Interactive robot helps older people exercise and detects underlying health problems
October 16, 2018 - What you need to know about autism spectrum disorder
October 16, 2018 - Antidepressants can be used to treat Alzheimer’s disease
October 16, 2018 - Study uncovers important role of PRMT1 in dilated cardiomyopathy
October 16, 2018 - Nutritional quality of breakfast linked to cardiovascular and metabolic risk factors in children
October 16, 2018 - Study uses novel approach to investigate genetic origins of mental illnesses
October 16, 2018 - Scientists develop dual anthrax-plague vaccine
October 16, 2018 - Poor Outcomes for Hispanic Infants With Congenital Heart Dz
October 16, 2018 - Global study finds youngest in class more likely to be diagnosed with ADHD
October 16, 2018 - Researchers sequence two selfish genes in the fungus Neurospora intermedia
October 16, 2018 - Survey results highlight the need for better communication between patients and HCPs about bacterial vaginosis
October 16, 2018 - Researchers develop fibrin-targeting immunotherapy to protect against neurodegeneration
October 16, 2018 - Researchers create open access database on healthy immunity
October 16, 2018 - Rice University chemist wins big award to study small surfaces
October 16, 2018 - Study finds 43% drop in stroke rate
October 16, 2018 - Researchers identify basic relationships of cell cycle and cellular senescence in the placenta
October 16, 2018 - UA professor receives NSF grant to develop antifouling materials for medical implants
October 16, 2018 - Obesity Doubles Odds for Colon Cancer in Younger Women
October 16, 2018 - Adults with ADHD not constrained in creativity
October 16, 2018 - Raising visibility for people and students with chronic illness and disability
October 16, 2018 - Allele awarded NIH grant to develop nanoantibody therapies for treatment of sepsis
October 16, 2018 - Only 59% of young adults undergoing surgery are fluid responsive
October 16, 2018 - Research points to potential new treatment for hearing loss
October 16, 2018 - MDI Biological Laboratory receives $1.2 million SEPA grant to promote data literacy
October 16, 2018 - Vast majority of dementia cases may arise from spontaneous genetic errors
October 16, 2018 - New project aims to deliver fast, effective treatment for autoimmune rheumatic diseases
October 16, 2018 - Study identifies molecular switch that controls fate of milk-producing breast cells
October 16, 2018 - Research shows diet has little influence on precursor to gout
October 16, 2018 - “Without Dr. Shumway doing his miracle work, three generations would not be here”: A Stanford heart transplant patient’s story
October 16, 2018 - Non-invasive brain stimulation sheds light on neurobiology underlying implicit bias
October 16, 2018 - Researchers demonstrate integrated technique to control production of cell therapeutics
October 16, 2018 - Breast tomosynthesis detects 34% more tumors than traditional mammography
October 16, 2018 - Rhode Island Hospital, Brown receive $800,000 grant to keep up fight against opioid epidemic
October 16, 2018 - UVA partners with health systems in AVIA network’s Medicaid Transformation Project
October 16, 2018 - Trevena Announces Oliceridine FDA Advisory Committee Meeting Outcome
October 16, 2018 - Study reveals early warning signs of heart problems in patients with newly diagnosed lupus
October 16, 2018 - Connecting the dots of Alzheimer’s disease
October 16, 2018 - New publication offers evidence-based content for global breast imaging medical community
October 16, 2018 - ‘EinsteinVision’ that improves hand-eye coordination of surgeons introduced at Harefield Hospital
October 16, 2018 - WRAIR clinical study evaluates safety and immunogenicity of Marburg vaccine
October 16, 2018 - Ketamine can be considered as alternative to opioids for short-term pain control in ED
October 16, 2018 - Endurance exercise training beneficially alters gut microbiota composition
October 15, 2018 - FDA Approves Yutiq (fluocinolone acetonide intravitreal implant) for Chronic Non-Infectious Posterior Segment Uveitis
October 15, 2018 - Birthing Options for Full-Term Pregnancy
October 15, 2018 - Stressed, toxic, zombie cells seen for first time in Alzheimer’s
October 15, 2018 - Concussion researchers study head motion in high school football hits | News Center
October 15, 2018 - Neuropsychiatric symptoms related to earliest stages of Alzheimer’s brain pathology
October 15, 2018 - Neck collar device may help protect the brain of female high school soccer players
October 15, 2018 - Research reveals how the inner ear processes speech
October 15, 2018 - Many parents still skeptical about safety and effectiveness of flu shot, survey finds
October 15, 2018 - Payer Policies May Discourage Non-Pharma Tx for Low Back Pain
October 15, 2018 - Exercise may delay cognitive decline in people with rare Alzheimer’s disease
October 15, 2018 - Researchers modify CRISPR to reorganize genome | News Center
October 15, 2018 - Innovative brain tumor operation set to tailor to patients’ needs
October 15, 2018 - Findings offer new insight into early changes that occur during AD pathology
October 15, 2018 - Neurons regulating reproductive hormone release have different activity in epileptic mice
October 15, 2018 - More parents are concerned about taking babies swimming in public pools
October 15, 2018 - Health Tip: Know the Risk Factors for Lower Back Pain
October 15, 2018 - Study shows cigarillo flavors enhanced by high-intensity sweeteners
October 15, 2018 - Study traces hospital-acquired bloodstream infections to patients’ own bodies | News Center
October 15, 2018 - Abnormal vision in childhood can affect development of brain areas responsible for attention
October 15, 2018 - Study highlights need for increased support for alcohol-related liver disease patients
October 15, 2018 - Color-changing contact lens could help doctors to monitor eye disease medications
October 15, 2018 - Tobacco heating products cause less staining to teeth than conventional cigarettes
October 15, 2018 - Young adults who are obese can expect to lose up to 10 years in life expectancy
October 15, 2018 - Scientists uncover how proteins meet on the cell membrane
New Drug Shows Promise for Progressive Form of MS

New Drug Shows Promise for Progressive Form of MS

image_pdfDownload PDFimage_print

Source: Getty Images

In a phase 2 clinical trial, an investigational anti-inflammatory drug called ibudilast was found to be superior to placebo in slowing the progression of brain atrophy in patients with progressive multiple sclerosis. The study, conducted at 28 sites around the country, including Columbia University Irving Medical Center, was published last month in the New England Journal of Medicine.

Why it Matters

About a dozen drugs have been approved for the treatment of relapsing-remitting MS, but few therapies are available for the progressive stage of the disease.

“We’re very encouraged by the results. This opens a new avenue of hope for patients with progressive MS, which has been very difficult to treat,” says study co-author Claire S. Riley, MD, assistant professor of neurology at Columbia University Vagelos College of Physicians and Surgeons and medical director of the Multiple Sclerosis Center at Columbia.


MS is characterized by a breakdown of myelin, a fatty substance that surrounds axons (part of the nerve cell that transmits signals between brain cells). When myelin degrades, communication between brain cells slows down, causing symptoms such as muscle weakness and problems with thinking and memory. In the most common form of the disease, relapsing-remitting MS, symptoms occur then disappear for weeks or months. Most people with relapsing-remitting disease eventually develop secondary progressive MS, in which symptoms worsen as the brain atrophies. About 15 percent of MS patients have primary progressive MS, in which the disease progresses with the onset of symptoms, without early relapses or remissions. MS is estimated to affect 400,000 people in the United States and 2 million people worldwide.

This opens a new avenue of hope for patients with progressive MS, which has been very difficult to treat.

Ibudilast, which is made by MediciNova, has been marketed in South Korea and Japan since 1989 for the treatment of dizziness after stroke and bronchial asthma. In the United States, it is being studied as a treatment for ALS (another neurodegenerative disorder) and for drug addiction.

What’s New

In this trial, 255 patients with primary or secondary progressive MS were randomized to receive oral ibudilast or placebo for almost two years. The patients ranged in age from 18 to 65, with an average disease duration of 12 years. Using magnetic resonance imaging, the researchers found that patients taking ibudilast had 48 percent less brain atrophy compared with controls. The drug was well tolerated but was associated with higher rates of gastrointestinal side effects, headache, and depression than placebo.

What it Means

Ibudilast appears to be safe and effective for the treatment of patients with progressive MS, although phase 3 clinical trials must demonstrate the drug’s effectiveness in clinical outcomes before it can receive FDA approval. 

What’s Next 

MedicaNova is currently looking at opportunities to begin phase 3 trials of ibudilast in patients with progressive MS.


This study looked at brain volume, not symptoms. However, brain shrinkage in MS is usually associated with declines in physical and cognitive function. “We can detect brain volume changes more accurately than changes in physical or cognitive function, which is why the study used brain volume change as the primary outcome,” explains Riley. “This allowed us to obtain results over a shorter period of time with fewer patients. Further studies are needed to determine if ibudilast has any effect on symptoms or neurologic disability.”

The drug was tested only in patients with progressive MS, not those with relapsing-remitting disease. If phase 3 trials prove that ibudilast is effective for those with progressive MS, it may be considered for use in a broader swath of the MS population, says Riley.

More Info

The study, “Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis,” was published Aug. 30, 2018, in the New England Journal of Medicine.

Claire S. Riley is assistant professor of neurology and medical director of the Multiple Sclerosis Center at Columbia University Vagelos College of Physicians and Surgeons.

The other authors are listed in the paper.

The study was supported by grants from the National Institute of Neurological Disorders and Stroke (U01NS082329), the National Multiple Sclerosis Society, and MediciNova.

Tagged with:

About author

Related Articles